The regulatory gears in the U.S. are increasingly creaking under the weight of new, complex drug technologies and intensifying overseas clinical trials competition from countries like China and Australia.
Now, the Department of Health and Human Services is making moves to speed early drug research under a new plan dubbed Operation Trialblazer. The blueprint, which involves initiatives at multiple federal agencies, including the Food and Drug Administration and the National Institutes of Health, focuses on modernizing regulations and processes, improving patient access and participation, and enhancing the use of data and technology to streamline the regulatory process.
It’s the latest in a series of actions aimed at supporting drug research. But whether the new reforms will make a meaningful impact is an open question.
“It's a step in the correct direction, but the reality is regulatory speed does not necessarily equate to scientific success,” said Dr. Francisco Beca, chief medical officer at QuantHealth, an AI clinical trial company.
What also matters, he noted, is ensuring strong trial design, an area where sponsors often fall short.
